Development of bone-targeted catalase derivatives for inhibition of bone metastasis of tumor cells in mice

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 552-557

  Zheng, Yunlong ^a   Nishikawa, Makiya ^a   Ikemura, Mai ^a   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cancer; Conjugation; PEGylation; Protein delivery; Targeted drug delivery

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATALASE; CATALASE 3,5 DI(ETHYLAMINO 2,2 BISPHOSPHONO)BENZOIC ACID; FIREFLY LUCIFERASE; INDIUM CHLORIDE IN 111; MACROGOL CATALASE; MACROGOL CATALASE 3,5 DI(ETHYLAMINO 2,2 BISPHOSPHONO)BENZOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CONJUGATION; FEMUR; MALE; MELANOMA; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; RADIOACTIVITY; RAT; TIBIA; TISSUE DISTRIBUTION; TUMOR CELL;

EID: 84455188937     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22773     Document Type: Article

References (26)

1. Nishikawa M. 2008. Reactive oxygen species in tumor metastasis. Cancer Lett 266:53-59.
2. Nishikawa M, Hashida M, Takakura Y. 2009. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Del Rev 61:319-326.
3. Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M. 2006. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med 41:1449-1458.
4. Hyoudou K, Nishikawa M, Kobayashi Y, Mukai S, Ikemura M, Kuramoto Y, Yamashita F, Hashida M. 2007. Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice. J Control Release 119:121-127.
5. Hyoudou K, Nishikawa M, Umeyama Y, Kobayashi Y, Yamashita F, Hashida M. 2004. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: Quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 10:7685-7691.
6. Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M. 2005. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release 109:101-107.
7. Sen CK, Packer L. 1996. Antioxidant and redox regulation of gene transcription. FASEB J 10:709-720.
8. Suzuki YJ, Forman HJ, Sevanian A. 1997. Oxidants as stimulators of signal transduction. Free Radic Biol Med 22:269-285.
9. Droge W. 2002. Free radicals in the physiological control of cell function. Physiol Rev 82:47-95.
10. Coleman RE. 1997. Skeletal complications of malignancy. Cancer 80:1588-1594.
11. Costa L, Major PP. 2009. Effect of bisphosphonates on pain and quality of life in patients with bone metastasis. Nat Clin Pract Oncol 6:163-174.
12. Mundy GR. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
13. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. 2006. Current topics in pharmacological research on bone metabolism: Inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci 100:189-194.
14. Doschak MR, Kucharski CM, Wright JE, Zernicke RF, Uludag H. 2009. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm 6:634-640.
15. Hirabayashi H, Fujisaki J. 2003. Bone-specific drug delivery systems: Approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet 42:1319-1330.
16. Marcus Y, Sasson K, Fridkin M, Shecter Y. 2008. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: A study with gentamicin. J Med Chem 51:4300-4305.
17. Morioka M, Kamizono A, Takikawa H, Mori A, Ueno H, Kadowaki S, Nakano Y, Kato K, Umezawa K. 2010. Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem 18:1143-1148.
18. Bansal G, Gittens SA, Uludag H. 2004. A di(bisphosphonic acid) for protein coupling and targeting to bone. J Pharm Sci 93:2788-2799.
19. Yabe Y, Nishikawa M, Tamada A, Takakura Y, Hashida M. 1999. Tageted delivery and improved therapeutic potential of catalase by chemical modification: Combination with superoxide dismutase derivatives. J Pharmacol Exp Ther 289:1176-1184.
20. Ames BN. 1966. Assay of inorganic phosphate, total phosphatases. Methods Enzymol 8:115-117.
21. Zhang S, Gangal G, Uludag H. 2007. "Magic bullets" bone diseases: Progress in rational design of bone seeking medical agents. Chem Soc Rev 36:507-531.
22. Yabe Y, Koyama Y, Nishikawa M, Takakura Y, Hashida M. 1999. Hepatocyte-specific distribution of catalase and its inhibitory effect on hepatic ischemia/reperfusion injury in mice. Free Radic Res 30:265-274.
23. Ma SF, Nishikawa M, Katsumi H, Yamashita F, Hashida M. 2006. Liver targeting of catalase by cationization for prevention of acute liver failure in mice. J Control Release 110:273-282.
24. Talmage RV. 1970. Morphological and physiological considerations in a new concept of calcium transport in bone. Am J Anat 129:467-476.
25. Wu S, Dahut WL, Gulley JL. 2007. The use of bisphosphonates in cancer patients. Acta Oncol 46:581-591.
26. Cremers SC, Pillai G, Papapoulos SE. 2005. Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551-570.